# US 2001/0044453 A1 · Combination drug therapy for glycolipid storage diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0044453 A1
- Document ID: US20010044453A1
- Status: Published application
- Kind: A1
- Application number: 09/859,928
- Filed: 2001-05-17
- Published: 2001-11-22
- Earliest claimed: 1999-07-26
- Assignees: G. D. Searle & Co.
- Inventors: Gary S. Jacob; Raymond A. Dwek
- Web page: https://patentgrep.com/patent/US20010044453A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A novel combination drug therapy is disclosed for the treatment of a patient affected with Gaucher's disease or other such glycolipid storage diseases. The method comprises administering to said patient a therapeutically effective amount of both a N-alkyl derivative of deoxynojirimycin (DNJ) and a glucocerebrosidase enzyme to alleviate or inhibit the glycolipid storage disease. The alkyl group has from about two to about 20 carbon atoms and preferably is butyl, nonyl or decyl.

## Claims

### Claim 1

The method of treating a patient affected with a glycolipid storage disease comprising administering to said patient both a N-alkyl derivative of deoxynojirimycin having from about two to about twenty carbon atoms in the alkyl chain and a glucocerebrosidase enzyme in an amount effective for alleviating or inhibiting said glycolipid storage disease.

### Claim 2 (depends on 1)

The method of claim 1 in which the N-alkyl derivative of deoxynojirimycin contains four to six carbon atoms in the alkyl chain.

### Claim 3 (depends on 2)

The method of claim 2 in which the N-alkyl derivative of deoxynojirimycin is N-butyl-DNJ.

### Claim 4 (depends on 1)

The method of claim 1 in which the N-alkyl derivative of deoxynojirimycin is N-nonyl-DNJ or N-decyl-DNJ.

### Claim 5 (depends on 4)

The method of claim 4 in which the N-alkyl derivative of deoxynojirimycin is N-nonyl-DNJ.

### Claim 6 (depends on 1)

The method of claim 1 in which the glycolipid storage disease is Gaucher's disease.

### Claim 7 (depends on 3)

The method of claim 3 in which the glycolipid storage disease in Gaucher's disease.

### Claim 8 (depends on 5)

The method of claim 5 in which the glycolipid storage disease is Gaucher's disease.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method as in any one of claims 1-8, in which the N-alkyl derivative of deoxynojirimycin is administered in a dose of from about 0.1 to about 1000 mg and the glucocerebrosidase is administered in a dose of about 7.5 to about 60 U per kilogram of weight of said patient in a pharmaceutically acceptable diluent or carrier.

### Claim 10

A combination drug composition comprising a N-alkyl derivative of deoxynojirimycin having from about two to about twenty carbon atoms in the alkyl chain and a glucocerebrosidase enzyme in a pharmaceutically acceptable diluent or carrier.

### Claim 11 (depends on 10)

The composition of claim 10 in which the N-alkyl derivative of deoxynojirimycin is N-butyl-DNJ.

### Claim 12 (depends on 10)

The composition of claim 10 in which the N-alkyl derivative of deoxynojirimycin is N-nonyl-DNJ or N-decyl-DNJ.

### Claim 13 (depends on 12)

The composition of claim 12 in which the N-alkyl derivative of deoxynojirimycin is N-nonyl-DNJ.
